OCGN Logo

Ocugen, Inc. (OCGN) 

NASDAQ
Market Cap
$284.49M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
649 of 776
Rank in Industry
354 of 433

Largest Insider Buys in Sector

OCGN Stock Price History Chart

OCGN Stock Performance

About Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development …

Insider Activity of Ocugen, Inc.

Over the last 12 months, insiders at Ocugen, Inc. have bought $0 and sold $0 worth of Ocugen, Inc. stock.

On average, over the past 5 years, insiders at Ocugen, Inc. have bought $502,419 and sold $9.67M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 200,278 shares for transaction amount of $99,999 was made by Zhang Junge (director) on 2023‑06‑14.

List of Insider Buy and Sell Transactions, Ocugen, Inc.

2023-06-14Purchasedirector
200,278
0.0886%
$0.50$99,999+8.98%
2023-02-16SaleChief Executive Officer
100,000
0.046%
$1.08$108,000-49.12%
2023-01-17SaleChief Executive Officer
100,000
0.045%
$1.28$128,000-56.90%
2022-12-16SaleChief Executive Officer
95,809
0.0407%
$1.43$137,007-62.61%
2022-10-14SaleChief Executive Officer
100,000
0.0484%
$1.66$166,000-49.17%
2022-10-06Saledirector
4,500
0.0021%
$1.83$8,235-54.28%
2022-08-11Sale
42,000
0.0211%
$2.91$122,220-58.40%
2022-07-18Sale
7,500
0.0036%
$2.57$19,275-49.19%
2022-07-14SaleChief Executive Officer
150,000
0.0716%
$2.72$408,000-52.09%
2022-05-13SaleChief Executive Officer
125,000
0.0529%
$1.92$240,000-23.33%
2022-04-18Sale
7,500
0.0038%
$2.83$21,225-33.85%
2022-03-16SaleChief Executive Officer
81,823
0.0367%
$2.65$216,831-31.01%
2022-02-14SaleChief Executive Officer
90,000
0.045%
$3.74$336,600-39.01%
2022-01-18Saledirector
7,500
0.0037%
$4.07$30,525-41.25%
2021-12-16SaleChief Executive Officer
115,000
0.0613%
$5.22$600,300-50.70%
2021-11-16SaleChief Executive Officer
115,000
0.0583%
$8.04$924,600-67.77%
2021-11-03Saledirector
150,300
0.1049%
$17.32$2.6M-79.03%
2021-11-02Saledirector
149,700
0.0772%
$15.75$2.36M-82.93%
2021-11-02Saledirector
25,000
0.0131%
$16.01$400,250-82.93%
2021-11-02Saledirector
15,000
0.0074%
$15.00$225,000-82.93%

Insider Historical Profitability

<0.0001%
Lewis Michael
3610570
1.2543%
$0.9921
Wilmslow Estates Ltd10 percent owner
3610570
1.2543%
$0.9921
Musunuri ShankarChief Executive Officer
2190073
0.7608%
$0.99216<0.0001%
Sofinnova Venture Partners VIII, L.P.10 percent owner
2085848
0.7246%
$0.9911
SPLIT ROCK PARTNERS II, LP10 percent owner
1661495
0.5772%
$0.9921<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$19.68M4.6612M-0.34%-$66,201.88<0.0001
BlackRock$6.23M1.483.8M+2.87%+$173,772.77<0.0001
Geode Capital Management$5.27M1.253.21M+9.68%+$465,155.34<0.0001
Goldman Sachs$4.28M1.012.61MNew+$4.28M<0.01
Millennium Management LLC$3.16M0.751.93M+368.6%+$2.48M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.